September 18, 2008
Dermatologists Continue to Use Enbrel Over Humira As First-Line Biologic Therapy for the Treatment of Psoriasis
WALTHAM, Mass., Sept. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 77 percent of surveyed dermatologists name Amgen/Wyeth/Takeda's Enbrel as their preferred first-line biologic therapy. The critical factors driving surveyed dermatologists' use of Enbrel ahead of Abbott/Eisai's Humira are its perceived better side-effect/safety profile and wealth of long-term safety data, as well as their own familiarity with the drug.
The new report entitled Treatment Algorithms in Psoriasis finds that 60 percent of surveyed dermatologists choose Enbrel as a first-line biologic therapy because of their familiarity and experience with the drug; 59 percent choose Enbrel because of their perception that its side-effect/safety profile is superior to that of Humira. On the other hand, surveyed dermatologists who choose to prescribe Humira over Enbrel do so for very different reasons. Fifty-one percent of surveyed dermatologists state that Humira's less frequent dosing (once every two weeks versus once or twice weekly) influences their choice of this agent over Enbrel as a first-line biologic therapy and 45 percent prescribe Humira as a first-line biologic drug because of its better efficacy in clearing psoriatic plaques.
The report also finds that 66 percent of surveyed dermatologists who are familiar with Centocor/ Medarex/Janssen-Cilag's interleukin-12/23 inhibitor Stelara (ustekinumab) plan to prescribe the drug when it becomes available. Stelara is generating excitement among interviewed experts because of its high response rates and the potential for long-term remissions. Surveyed dermatologists who expect to incorporate Stelara into their therapeutic arsenal say that the greatest percentage of its total use will stem from second-line therapy. This physician group estimates that 20 percent of their use of Stelara will be in first-line therapy, whereas 40 percent of their prescriptions for the drug will be as a second-line treatment.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
About Decision Resources
Decision Resources ( http://www.decisionresources.com/ ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/ .
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 [email protected] [email protected]
Web site: http://www.decisionresources.com/http://www.decisionresourcesinc.com/